Table 3. The frequency of oxaliplatin-based regimens used in either locally advanced, metastatic or both stages between KRAS mutant and wild-type patients.

	Oxaliplatin-based regimens used in locally advanced stage only		Oxaliplatin-based regimens used for at least one month in metastatic stage only		Oxaliplatin-based regimens used in both locally advanced and metastatic stages
KRAS mutant patients	19/169 (11%)	P = 0.075	116/169 (69%)	P = 0.084	15/169 (9%)	P = 0.24
KRAS wild-type patients	14/225 (6%)		172/225 (76%)		13/225 (6%)